[Four cases of XXXX treated by chemoradiotherapy].

@entity1 @entity5 @entity75 @entity957 @entity1139 @entity3 @entity1487
We reviewed clinical records of 4 cases with @entity957 in anus to evaluate the clinical effectiveness of the chemoradiotherapy. The radiation therapy consisted of 40 Gy was delivered to pelvis and bilateral inguinal lesion, and perianal booster dose of 20 Gy, in fractions of 2.0 Gy per day, was given five days a week. On the first day of radiation therapy, 750 mg/m2 of @entity1487 in the form of a continuous 24-hour infusion for 5 days was given. On the first day of chemotherapy, 10 mg/m2 of @entity1139 was also given as a single bolus infusion. 5-FU and @entity1139 were administered 4 times every 4 weeks. Three @entity1 had T2 @entity5 , and one @entity1 had T1 @entity5 . One @entity1 had @entity3 in para-aortic and Virchow lymph node. No @entity1 had hematogenous @entity3 . Grade 1 or 2 adverse effects occurred in 3 @entity1 during chemoradiotherapy, but the completion of chemoradiotherapy was achieved in all of the 4 @entity1 . All @entity1 had complete response in the @entity75 after chemoradiotherapy. No @entity1 had any sign of recurrence in @entity75 . Chemoradiotherapy was expected to be a safe and effective treatment to improve prognosis for @entity957 .
